terfenadine has been researched along with Long QT Syndrome in 48 studies
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using moxifloxacin and terfenadine, which are known to induce benign and malignant QT interval prolongation, respectively, we analysed whether halothane-anaesthetized microminipigs are an appropriate model for assessing the risk of drug-induced long QT syndrome." | 7.85 | Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Matsukura, S; Naito, AT; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "A 36-year-old female was given terfenadine 120 mg/day for hay fever, and itraconazole 100 mg twice daily for mycosis." | 7.69 | [Syncopes during simultaneous use of terfenadine and itraconazole]. ( Froger, CL; Romkes, JH; Westerhof, PW; Wever, EF, 1997) |
| "Terfenadine is a widely used antihistamine." | 5.29 | Torsade de pointes induced by terfenadine in a patient with long QT syndrome. ( Kim, SS; Koh, KK; Rim, MS; Yoon, J, 1994) |
| "Arsenic trioxide (As2O3) has been verified as a breakthrough in the management of acute promyelocytic leukemia in recent decades." | 3.85 | Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism. ( Feng, L; Li, B; Li, F; Liu, Y; Shi, Y; Wang, J; Yan, M, 2017) |
| "Using moxifloxacin and terfenadine, which are known to induce benign and malignant QT interval prolongation, respectively, we analysed whether halothane-anaesthetized microminipigs are an appropriate model for assessing the risk of drug-induced long QT syndrome." | 3.85 | Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Matsukura, S; Naito, AT; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "For terfenadine, TRIaD predicts drug-induced proarrhythmia: with λ prolongation, Torsade de Pointes is preferred, otherwise ventricular tachycardia/ventricular fibrillation." | 3.77 | Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. ( De Clerck, F; Dujardin, K; Dumotier, B; Hoffmann, P; Hondeghem, LM, 2011) |
| "Administration of the antihistamine terfenadine (Seldane) to patients may result in acquired long QT syndrome and ventricular arrhythmias." | 3.69 | HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. ( Brown, AM; Dumaine, R; Roy, M, 1996) |
| "A 36-year-old female was given terfenadine 120 mg/day for hay fever, and itraconazole 100 mg twice daily for mycosis." | 3.69 | [Syncopes during simultaneous use of terfenadine and itraconazole]. ( Froger, CL; Romkes, JH; Westerhof, PW; Wever, EF, 1997) |
| "Terfenadine has been reported to cause cardiac death." | 1.38 | Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? ( Gallacher, DJ; Hermans, AN; Lu, HR, 2012) |
| "The long QT syndrome is a rare disease." | 1.33 | Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs. ( Codreanu, A; de Chillou, C; Moneret-Vautrin, DA, 2006) |
| "Terfenadine is a widely used antihistamine." | 1.29 | Torsade de pointes induced by terfenadine in a patient with long QT syndrome. ( Kim, SS; Koh, KK; Rim, MS; Yoon, J, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (29.17) | 18.2507 |
| 2000's | 25 (52.08) | 29.6817 |
| 2010's | 8 (16.67) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| Pearlstein, R | 1 |
| Vaz, R | 1 |
| Rampe, D | 1 |
| Zhang, HC | 1 |
| Derian, CK | 1 |
| McComsey, DF | 1 |
| White, KB | 1 |
| Ye, H | 1 |
| Hecker, LR | 1 |
| Li, J | 1 |
| Addo, MF | 1 |
| Croll, D | 1 |
| Eckardt, AJ | 1 |
| Smith, CE | 1 |
| Li, Q | 1 |
| Cheung, WM | 1 |
| Conway, BR | 1 |
| Emanuel, S | 1 |
| Demarest, KT | 1 |
| Andrade-Gordon, P | 1 |
| Damiano, BP | 1 |
| Maryanoff, BE | 1 |
| Bonate, PL | 1 |
| Yan, M | 1 |
| Feng, L | 1 |
| Shi, Y | 1 |
| Wang, J | 1 |
| Liu, Y | 1 |
| Li, F | 1 |
| Li, B | 1 |
| Cao, X | 1 |
| Wada, T | 1 |
| Nakamura, Y | 3 |
| Matsukura, S | 1 |
| Izumi-Nakaseko, H | 1 |
| Ando, K | 1 |
| Naito, AT | 1 |
| Sugiyama, A | 6 |
| Romero, L | 1 |
| Trenor, B | 1 |
| Yang, PC | 1 |
| Saiz, J | 1 |
| Clancy, CE | 1 |
| Wiśniowska, B | 1 |
| Polak, S | 1 |
| Dabhi, J | 1 |
| Mehta, A | 1 |
| Grilo, LS | 1 |
| Carrupt, PA | 1 |
| Daina, A | 1 |
| Hondeghem, LM | 1 |
| Dujardin, K | 1 |
| Hoffmann, P | 1 |
| Dumotier, B | 1 |
| De Clerck, F | 1 |
| Lu, HR | 1 |
| Hermans, AN | 1 |
| Gallacher, DJ | 1 |
| Pareja, K | 1 |
| Chu, E | 1 |
| Dodyk, K | 1 |
| Richter, K | 1 |
| Miller, A | 1 |
| Fossa, AA | 1 |
| DePasquale, MJ | 1 |
| Raunig, DL | 1 |
| Avery, MJ | 1 |
| Leishman, DJ | 1 |
| Satoh, Y | 3 |
| Takahara, A | 4 |
| Shimizu-Sasamata, M | 1 |
| Sato, S | 1 |
| Miyata, K | 1 |
| Hashimoto, K | 5 |
| Brown, AM | 2 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Abe, J | 1 |
| Sawada, Y | 1 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Heist, EK | 1 |
| Ruskin, JN | 1 |
| Ishida, Y | 1 |
| Wang, K | 1 |
| Roden, DM | 1 |
| Rufke, C | 1 |
| Nieber, K | 1 |
| Moss, AJ | 1 |
| Crumb, W | 1 |
| Llorca, PM | 1 |
| Lancon, C | 1 |
| Thomas, GP | 1 |
| Garay, RP | 1 |
| Hameg, A | 1 |
| Sisáková, M | 1 |
| Toman, O | 1 |
| Floriánová, A | 1 |
| Kadlecová, J | 1 |
| Chroust, K | 1 |
| Papousek, I | 1 |
| Spinar, J | 1 |
| Couderc, JP | 1 |
| Lehman, JM | 1 |
| Blaiss, MS | 1 |
| Moneret-Vautrin, DA | 1 |
| de Chillou, C | 1 |
| Codreanu, A | 1 |
| Hughes, DA | 1 |
| Bayoumi, AM | 1 |
| Pirmohamed, M | 1 |
| Koh, KK | 1 |
| Rim, MS | 1 |
| Yoon, J | 1 |
| Kim, SS | 1 |
| Barragán Acea, A | 1 |
| García González, M | 1 |
| Rodríguez Gaspar, M | 1 |
| de Armas Trujillo, D | 1 |
| Conti, CR | 1 |
| Flockhart, DA | 1 |
| Rosen, MR | 1 |
| Roy, M | 1 |
| Dumaine, R | 1 |
| Romkes, JH | 1 |
| Froger, CL | 1 |
| Wever, EF | 1 |
| Westerhof, PW | 1 |
| Pasco, J | 1 |
| Pinto, YM | 1 |
| van Gelder, IC | 1 |
| Heeringa, M | 1 |
| Crijns, HJ | 1 |
| Weber, KT | 1 |
| Shuster, J | 1 |
| Khilnani, G | 1 |
| Dhar, S | 1 |
| Hazra, PK | 1 |
| Malakar, S | 1 |
| Mistri, G | 1 |
| Rajamani, S | 1 |
| Anderson, CL | 1 |
| Anson, BD | 1 |
| January, CT | 1 |
| Feychting, K | 1 |
| Myrenfors, P | 1 |
| Zimmermann, M | 1 |
| Duruz, H | 1 |
| Guinand, O | 1 |
| Broccard, O | 1 |
| Levy, P | 1 |
| Lacatis, D | 1 |
| Bloch, A | 1 |
7 reviews available for terfenadine and Long QT Syndrome
| Article | Year |
|---|---|
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Topics: Cation Transport Proteins; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; ER | 2003 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cat | 2003 |
Drugs, hERG and sudden death.
Topics: Death, Sudden, Cardiac; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Ether-A-Go-Go Potassiu | 2004 |
Long QT syndrome: reduced repolarization reserve and the genetic link.
Topics: Anti-Arrhythmia Agents; Disease Susceptibility; Female; Genotype; Histamine H1 Antagonists; Humans; | 2006 |
[Long QT interval. Interaction of terfenadine and itraconazole].
Topics: Antifungal Agents; Histamine H1 Antagonists; Humans; Itraconazole; Long QT Syndrome; Onychomycosis; | 2006 |
Selecting the optimal oral antihistamine for patients with allergic rhinitis.
Topics: Administration, Oral; Cardiovascular System; Central Nervous System; Cetirizine; Drug Interactions; | 2006 |
Of oocytes and runny noses.
Topics: Animals; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Pota | 1996 |
41 other studies available for terfenadine and Long QT Syndrome
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
Topics: Animals; Cell Line; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glycogen Synthase Kina | 2005 |
QTc interval analysis-an ever-evolving endeavor.
Topics: Dose-Response Relationship, Drug; Drug Approval; Drug Recalls; Electrocardiography; Humans; Long QT | 2021 |
Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
Topics: Action Potentials; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ERG1 Potassium Channel; HEK2 | 2017 |
Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome.
Topics: Anesthetics, Inhalation; Animals; Arrhythmias, Cardiac; Blood Pressure; Disease Models, Animal; Dose | 2017 |
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Astemizole; Cisapride; Computer Simulation; Gene Expressi | 2014 |
Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example.
Topics: Adult; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Female; Histamine H1 | 2016 |
QT prolongation and safety in the Indian population.
Topics: Astemizole; Cisapride; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Electroc | 2007 |
Stereoselective block of hERG channel by bupivacaine scrutinized at molecular level.
Topics: Bupivacaine; Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Models | 2010 |
Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine.
Topics: Action Potentials; Animals; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart; Hi | 2011 |
Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Appendage; Biological Transport; Cells, C | 2012 |
Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.
Topics: Bepridil; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Potass | 2013 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart | 2002 |
Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems.
Topics: Action Potentials; Animals; Cation Transport Proteins; Cell Line; DNA-Binding Proteins; Dogs; Electr | 2003 |
Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation.
Topics: Action Potentials; Adrenergic beta-Antagonists; Algorithms; Anesthetics, Inhalation; Animals; Chroma | 2005 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians.
Topics: Anti-Arrhythmia Agents; Antipsychotic Agents; Histamine H1 Antagonists; Humans; Long QT Syndrome; Ri | 2005 |
Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias.
Topics: Animals; Atrioventricular Node; Bradycardia; Catheter Ablation; Dogs; Dose-Response Relationship, Dr | 2006 |
Drug-induced QT prolongation: an update.
Topics: Electrocardiography; Fluoroquinolones; Humans; Long QT Syndrome; Quinidine; Terfenadine | 2006 |
Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Calcium Channels; Cell Line; Dose-Response Relat | 2006 |
[Extension of QT interval as a consequence of risk factor accumulation--case study].
Topics: Adult; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Drug Interactions; Female; Histamin | 2006 |
QT interval prolongation and beyond.
Topics: Animals; Anti-Allergic Agents; Dogs; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; Terf | 2006 |
Comparison of four rate-correction algorithms for the ventricular repolarization period in assessing net effects of IKr blockers in dogs.
Topics: Action Potentials; Algorithms; Animals; Blood Pressure; Delayed Rectifier Potassium Channels; Dogs; | 2006 |
Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Asthmatic Agents; Butyrophenones; Cetirizine; Conjunct | 2006 |
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?
Topics: Algorithms; Anti-Allergic Agents; Decision Support Techniques; Government Regulation; Humans; Long Q | 2007 |
Torsade de pointes induced by terfenadine in a patient with long QT syndrome.
Topics: Adult; Electrocardiography; Female; Humans; Long QT Syndrome; Terfenadine; Torsades de Pointes; Urti | 1994 |
[Ventricular arrhythmia induced by terfenadine treatment].
Topics: Adult; Female; Humans; Long QT Syndrome; Terfenadine | 1995 |
The nonsedating antihistamine scare.
Topics: Astemizole; Drug Interactions; Drug Therapy, Combination; Humans; Long QT Syndrome; Terfenadine | 1994 |
Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic?
Topics: Death, Sudden, Cardiac; Drug Interactions; Heart; Histamine H1 Antagonists; Humans; Long QT Syndrome | 1996 |
HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.
Topics: Animals; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Pota | 1996 |
[Syncopes during simultaneous use of terfenadine and itraconazole].
Topics: Adult; Anti-Allergic Agents; Antifungal Agents; Cardiotonic Agents; Female; Humans; Isoproterenol; I | 1997 |
What has the patient been taking?
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chlorothiazide; Cimetidine; Diagnosis, Differential; | 1998 |
QT lengthening and life-threatening arrhythmias associated with fexofenadine.
Topics: Aged; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male; Syncope; Tachyc | 1999 |
A dilemma on Orchid Island.
Topics: Aged; Beverages; Citrus; Glycyrrhiza; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male; Plan | 1999 |
Fexofenadine and prolonged QT intervals.
Topics: Aged; Drug Monitoring; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male | 1999 |
Terfenadine should be withdrawn from clinical use.
Topics: Drug Interactions; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Terfenad | 1999 |
Fexofenadine-induced QT prolongation: a myth or fact?
Topics: Controlled Clinical Trials as Topic; Histamine H1 Antagonists; Humans; Long QT Syndrome; Terfenadine | 2000 |
Severe cardiac arrhythmia on fexofenadine?
Topics: Adverse Drug Reaction Reporting Systems; Histamine H1 Antagonists; Humans; Long QT Syndrome; Terfena | 2000 |
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
Topics: Anti-Arrhythmia Agents; Cell Line; Dose-Response Relationship, Drug; Electric Conductivity; ERG1 Pot | 2002 |
[Severe effects of terfenadine overdose on the heart].
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Female; Heart Rate; Human | 1992 |
Torsades de Pointes after treatment with terfenadine and ketoconazole.
Topics: Adult; Cardiac Pacing, Artificial; Dermatomycoses; Drug Therapy, Combination; Electrocardiography, A | 1992 |